{
    "ticker": "MRSN",
    "name": "Mersana Therapeutics, Inc.",
    "description": "Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative antibody-drug conjugates (ADCs) that target cancer. Founded in 2001 and headquartered in Cambridge, Massachusetts, Mersana is dedicated to creating therapies that improve patient outcomes while minimizing side effects. The company's proprietary platform, Dolasynthen, enables the development of ADCs with optimized drug delivery and efficacy. Mersana's lead product candidate, XMT-1536, is designed to target and kill cancer cells expressing the NaPi2b protein, which is prevalent in various solid tumors, including ovarian cancer. The company is also advancing other candidates in its pipeline, targeting different tumor types with the goal of addressing unmet medical needs in oncology. Mersana Therapeutics has established partnerships and collaborations with leading pharmaceutical companies, leveraging its innovative technology to enhance cancer treatment options. The company's commitment to scientific excellence and patient-centric solutions drives its research and development efforts, aiming to make a meaningful impact in the field of oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2001",
    "website": "https://www.mersana.com",
    "ceo": "Anna Protopapas",
    "social_media": {
        "twitter": "https://twitter.com/MersanaTx",
        "linkedin": "https://www.linkedin.com/company/mersana-therapeutics/"
    },
    "investor_relations": "https://investors.mersana.com",
    "key_executives": [
        {
            "name": "Anna Protopapas",
            "position": "CEO"
        },
        {
            "name": "Mike McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "XMT-1536",
                "XMT-1592"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mersana Therapeutics, Inc. | Innovative Cancer Treatments",
        "meta_description": "Explore Mersana Therapeutics, Inc., a leader in antibody-drug conjugate development for cancer treatment. Learn about their innovative therapies and ongoing clinical trials.",
        "keywords": [
            "Mersana Therapeutics",
            "Antibody-Drug Conjugates",
            "Cancer Treatment",
            "XMT-1536",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Mersana Therapeutics known for?",
            "answer": "Mersana Therapeutics is known for its innovative antibody-drug conjugates aimed at treating cancer."
        },
        {
            "question": "Who is the CEO of Mersana Therapeutics?",
            "answer": "Anna Protopapas is the CEO of Mersana Therapeutics, Inc."
        },
        {
            "question": "Where is Mersana Therapeutics headquartered?",
            "answer": "Mersana Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Mersana's main products?",
            "answer": "Mersana's main products include XMT-1536 and XMT-1592, both focused on oncology."
        },
        {
            "question": "When was Mersana Therapeutics founded?",
            "answer": "Mersana Therapeutics was founded in 2001."
        }
    ],
    "competitors": [
        "CLVS",
        "BMY",
        "AMGN",
        "AZN"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "VRTX",
        "BMY"
    ]
}